"You think a 1/X000 chance of stroking in a hospital setting due to elevated blood pressure is going to stop them from taking it if it works?"
Depends what X is.
And due to the exclusion criteria we won't know if it's safe to use in poorly controlled hypertensive patients anyway.
Unless they do further studies pre-existing cardiovascular conditions are likely to be a contraindication if brilacidin is ever approved for any indication.
"You still seem really stuck on a very manageable non-lethal condition like blood pressure elevation being some show stopper for COVID patients dying in the ICU."
Those people are excluded from the study anyway, so your question is moot:
"The target population to be treated are patients with moderate to severe COVID-19, SARS-CoV-2 infection confirmed by positive standard polymerase chain reaction (PCR) test (or equivalent/ other approved diagnostic test) within 4 days prior to starting study treatment, and hospitalized with respiratory distress but not yet requiring high-level respiratory support (as defined in exclusion criterion #2). See inclusion/exclusion criteria.
Exclusion Criteria:
........
Requiring invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO) at the time of randomization.
.......
In the opinion of the investigator, progression to death is imminent and inevitable within the next 72 hours, irrespective of the provision of treatment, such as rapidly progressive multiorgan failure."
Market Data 
Markets 
AI
